Roche Holding AG (RHHVF) Stock Price & Analysis
Roche Holding AG (RHHVF) — price $484.28 (+3.69%), as of the Oct 23, 2026 trading session; market cap $334B. Expected results Feb 4, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Roche Holding AG · RHHVF · Healthcare · Drug Manufacturers - General
Roche Holding AG operates as a global healthcare leader, specializing in both pharmaceuticals and diagnostics.
Price as of Oct 23, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $484.28 | |
| Change on the day | +3.69% | |
| 52-week range | $318.81–$490.33 | |
| Market capitalisation | $334B | |
| Price / earnings (trailing) | 25.89 | |
| Shares traded on the day | 459 | |
| Beta (volatility vs the S&P 500) | 0.35 | |
| Dividends per share (last 12 months) | $12.41 | |
| Dividend yield (last 12 months) | 2.56% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
It could be a little bit lower, but we will see a little bit of a ramp-up of that effect in the second half.
Alan Hippe · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Roche Holding AG (RHHVF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 8, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 30, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 30, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 26, 2026, except a card that shows its own read date.
Watch the RHHVF film — every key number, told as a short cinematic story
~2 min · open the film
What is Roche Holding AG (RHHVF), and what does it report?
Short answer · as of
Roche Holding AG operates as a global healthcare leader, specializing in both pharmaceuticals and diagnostics. Healthcare / Drug Manufacturers General Headquarters: Grenzacherstrasse 124, Basel, 4070, CH. It employs 103,249 people and is led by Thomas Schinecker. In Q2 FY2026 it reported revenue of $36.49B and net income of $8.26B. The market values it at $334B.
What do the latest results show for Roche Holding AG (RHHVF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $36.49B. Against analyst estimates the company has EPS beat 4 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $38.91B Jul 23, 2026
- Latest report · revenue estimate
- $37.65B Jul 23, 2026
- Latest report · revenue vs estimate
- Above estimate Jul 23, 2026
- Latest report · EPS vs estimate
- Above estimate Jul 23, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 23, 2026 | $38.91B | $37.65B | $13.4200 | $12.5100 |
| Jan 29, 2026 | $38.56B | $39.22B | $10.5600 | $10.8300 |
| Jul 24, 2025 | $40.14B | $38.92B | $13.9700 | $13.1800 |
| Jan 30, 2025 | $33.74B | $33.90B | $9.4400 | $9.2500 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $36.49B | $8.26B | $10.20 (diluted) |
| Q4 FY2025 | $36.97B | $6.61B | $8.24 (diluted) |
| Q2 FY2025 | $38.49B | $8.96B | $11.16 (diluted) |
| Q4 FY2024 | $38.24B | $2.44B | $3.05 (diluted) |
What are the financial strengths and risks for Roche Holding AG (RHHVF)?
Short answer
The distress and quality screens read Altman Z 4.66 · Piotroski F 5. Trailing ratios: ROE 37.1% · ROA 12.6% · current ratio 1.23 · earnings yield 3.9% · free-cash-flow yield 5.5%.
What should you watch next at Roche Holding AG (RHHVF)?
Short answer · as of
The next earnings report is expected on Feb 4, 2027.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
It could be a little bit lower, but we will see a little bit of a ramp-up of that effect in the second half.
Alan Hippe ·
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
What has been published about Roche Holding AG (RHHVF)?
RHHVF Healthcare Stock FAQ
These answers are editorial: 1 of these 8 answers is drawn from the RHHVF research dossier (written Mar 15, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is RHHVF a good stock to buy?
Stock Expert AI does not rate RHHVF buy, sell or hold. Roche Holding AG has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the RHHVF stock price today?
The last price recorded on this page for Roche Holding AG (RHHVF) is $484.28, as of the Oct 23, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about RHHVF stock?
Analyst consensus on Roche Holding AG (RHHVF) is generally positive, reflecting the company's strong market position and diversified healthcare portfolio. Key valuation metrics, such as the P/E ratio and dividend yield, are closely monitored.
What are the key factors to evaluate for RHHVF?
Evaluate RHHVF on fundamentals, analyst consensus, and risk factors. P/E: 25.89x. The research collaboration agreement with Synlogic, Inc. for the treatment of inflammatory bowel disease (IBD) exemplifies this approach. Not financial advice.
How frequently does RHHVF data refresh on this page?
RHHVF's price is the last quote we recorded, from the Oct 23, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven RHHVF's recent stock price performance?
Roche Holding AG (RHHVF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio in pharmaceuticals and diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RHHVF overvalued or undervalued right now?
Roche Holding AG (RHHVF) trades at 25.89x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RHHVF before investing?
Before investing in Roche Holding AG (RHHVF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (42 figures)
The 42 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Alan Hippe (Jul 23, 2026): It could be a little bit lower, but we will see a little bit of a ramp-up of that effect in the second half. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. |
FMP — 33 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $484.28 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-26T12:24:49.983Z. | |
px.change | Change on the day | +3.69% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $334B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-23. FMP quote timestamp: 2026-10-23T20:00:00.000Z. Captured from FMP at 2026-10-26T12:24:49.012Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Feb 4, 2027 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | Roche Holding AG operates as a global healthcare leader, specializing in both pharmaceuticals and diagnostics. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | +$17.23 | FMP | Financial Modeling Prep (FMP) · quote | |
px.range52 | 52-week range | $318.81–$490.33 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 25.89 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 459 | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.35 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Drug Manufacturers General | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | Grenzacherstrasse 124, Basel, 4070, CH | FMP | Financial Modeling Prep (FMP) company profile | |
id.employees | Employees | 103,249 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Thomas Schinecker | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q2 FY2026 | $36.49B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | $8.26B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-07-23.revenue_actual | Revenue · reported — report date 2026-07-23 | $38.91B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-23.revenue_estimated | Revenue · estimate — report date 2026-07-23 | $37.65B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-23.eps_actual | EPS · reported — report date 2026-07-23 | $13.4200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-23.eps_estimated | EPS · estimate — report date 2026-07-23 | $12.5100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-29.revenue_actual | Revenue · reported — report date 2026-01-29 | $38.56B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-29.revenue_estimated | Revenue · estimate — report date 2026-01-29 | $39.22B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-29.eps_actual | EPS · reported — report date 2026-01-29 | $10.5600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-29.eps_estimated | EPS · estimate — report date 2026-01-29 | $10.8300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-24.revenue_actual | Revenue · reported — report date 2025-07-24 | $40.14B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-24.revenue_estimated | Revenue · estimate — report date 2025-07-24 | $38.92B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-24.eps_actual | EPS · reported — report date 2025-07-24 | $13.9700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-24.eps_estimated | EPS · estimate — report date 2025-07-24 | $13.1800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-01-30.revenue_actual | Revenue · reported — report date 2025-01-30 | $33.74B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-01-30.revenue_estimated | Revenue · estimate — report date 2025-01-30 | $33.90B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-01-30.eps_actual | EPS · reported — report date 2025-01-30 | $9.4400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-01-30.eps_estimated | EPS · estimate — report date 2025-01-30 | $9.2500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 4 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-20 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 4.66 · Piotroski F 5 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-26 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 37.1% · ROA 12.6% · current ratio 1.23 · earnings yield 3.9% · free-cash-flow yield 5.5% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 4 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $12.41 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 1 split-adjusted declared dividend with an ex-date in the 365 days to 2026-10-25, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 2.56% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-07-23.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($38.91B) with the recorded estimate ($37.65B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-23.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($13.4200) with the recorded estimate ($12.5100) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 1 fact from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-07-23. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-23.revenue_actual,earn.history.depth.2026-07-23.revenue_estimated,earn.history.depth.2026-07-23.revenue_actual.comparison,earn.history.depth.2026-07-23.eps_actual.comparison,earn.history.depth.2026-07-23.eps_actual,earn.history.depth.2026-07-23.eps_estimated,earn.history.depth.2026-01-29.revenue_actual,earn.history.depth.2026-01-29.revenue_estimated,earn.history.depth.2026-01-29.eps_actual,earn.history.depth.2026-01-29.eps_estimated,earn.history.depth.2025-07-24.revenue_actual,earn.history.depth.2025-07-24.revenue_estimated,earn.history.depth.2025-07-24.eps_actual,earn.history.depth.2025-07-24.eps_estimated,earn.history.depth.2025-01-30.revenue_actual,earn.history.depth.2025-01-30.revenue_estimated,earn.history.depth.2025-01-30.eps_actual,earn.history.depth.2025-01-30.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.